Valneva se - adr VALN.US 總覽分析
)VALN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
VALN 近期報酬表現
0.16%
Valneva se - adr
6.54%
同產業平均
0.41%
S&P500
與 VALN 同產業的標的表現
- CLRB Cellectar biosciences inc價值 2 分趨勢 3 分波段 4 分籌碼 1 分股利 1 分查看更多
VALN 公司資訊
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.